{"id":2399,"date":"2026-03-24T15:51:54","date_gmt":"2026-03-24T14:51:54","guid":{"rendered":"https:\/\/www.bayoocare.com\/unkategorisiert\/launch-strategy-for-medical-devices-bringing-your-medical-device-to-market-safely-and-successfully\/"},"modified":"2026-04-16T15:30:55","modified_gmt":"2026-04-16T13:30:55","slug":"launch-strategy-for-medical-devices-bringing-your-medical-device-to-market-safely-and-successfully","status":"publish","type":"post","link":"https:\/\/www.bayoocare.com\/en\/services\/launch-strategy-for-medical-devices-bringing-your-medical-device-to-market-safely-and-successfully\/","title":{"rendered":"Launch strategy for medical devices – bringing your medical device to market safely and successfully"},"content":{"rendered":"

<\/span><\/div><\/div><\/div>

Launch strategy for medical devices – bringing your medical device to market safely and successfully<\/h2><\/div>

A predictable market entry starts with the right strategy. We work with you to develop a customized launch strategy for your medical device, from initial risk classification to MDR approval and successful market launch in Europe. We dovetail regulatory requirements with clinical evidence and your commercial goals to create a clear, actionable roadmap. <\/p>\n<\/div>

Contact us now<\/span><\/a><\/div><\/div><\/div><\/div><\/div>

Launch strategy for medical devices
\n– bringing your medical device to market safely and successfully<\/h1><\/div>

A predictable market entry starts with the right strategy. We work with you to develop a customized launch strategy for your medical device, from initial risk classification to MDR approval and successful market launch in Europe. We dovetail regulatory requirements with clinical evidence and your commercial goals to create a clear, actionable roadmap. <\/p>\n<\/div>

Contact us now<\/span><\/a><\/div><\/div><\/div>
<\/span><\/div><\/div><\/div><\/div><\/div>

What makes a professional launch strategy<\/h2><\/div>

Many innovative medical products do not fail due to approval, but due to an inadequately prepared market launch. A well-founded launch strategy significantly reduces regulatory and commercial risks and shortens the time to satisfactory sales development. The more complex and innovative your product, the more important early, structured planning is – ideally two to three years before the planned market launch. <\/p>\n

A launch strategy for medical devices combines three levels: Regulatory market access according to MDR or IVDR, a sound understanding of the market and target customers and a clear go-to-market plan with a concrete timeline. Instead of just thinking “approval”, we work with you to plan how your product will be approved, positioned on the market and sustainably adopted. This includes pricing strategies, distribution channels, reimbursement issues and post-market activities right from the start. <\/p>\n

Our launch strategy is geared towards the entire product life cycle: from the development phase, clinical studies and conformity assessment to the start of sales and continuous market surveillance. We take into account the specific characteristics of regulated markets such as Germany and the EU, where, in addition to CE marking, reimbursement issues, market access measures and listing procedures are decisive for commercial success. <\/p>\n<\/div><\/div><\/div>

Classification and market access path
\nas a foundation<\/p><\/h2><\/div><\/div><\/div>

Every launch strategy starts with a precise analysis of your product and its classification into the appropriate MDR risk class – from Class I to III or according to IVDR. This classification largely determines your approval path, the required budget and the time to market.
\nWe derive the appropriate conformity assessment procedure, clarify the requirements and role of a notified body and create a realistic time and resource plan from a regulatory perspective. <\/p>\n<\/div><\/div><\/div>

<\/span><\/div><\/div><\/div>

This forms the foundation for your business case and enables reliable timetables for investors and stakeholders.<\/p>\n

Choosing the right classification path has far-reaching consequences: While Class I products are generally subject to self-certification, Class IIa and above products require the involvement of a Notified Body, which can add several months to the approval process. Current industry data shows that the average processing time for MDR certificates is twelve to eighteen months – a critical factor for your market entry strategy. <\/p>\n<\/div><\/div><\/div>

Approval strategy with a clear
\nEU focus<\/p><\/h2><\/div><\/div><\/div>

We define the regulatory pathway for your target markets with a focus on MDR, IVDR and the German Medical Device Implementation Act. If required, we also integrate the FDA route for the US market. We derive the necessary technical documentation, clinical data and tests from the regulatory requirements, always closely interlinked with your development plan. <\/p>\n

The centrepiece is the roadmap to CE marking: we structure all milestones, dependencies and critical paths, organize the involvement of the notified body at the right time and prepare you specifically for audits and reviews. In doing so, we keep an eye on the current MDR transition periods, which apply until the end of 2028 depending on the risk class. Contacting a notified body at an early stage can avoid delays of several months – an aspect that is often underestimated in practice. <\/p>\n<\/div><\/div><\/div>

Contact us<\/h3><\/div>

Do you want to launch your medical device safely and successfully? BAYOOCARE will work with you to develop a customized launch strategy – from MDR approval and market access to the go-to-market plan. Contact us now and arrange a non-binding consultation. <\/p>\n<\/div>

Your contact to us<\/span><\/a><\/div><\/div><\/div>
<\/i><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div><\/div><\/div>

Market and target customer analysis for well-founded decisions<\/h3><\/div>

In parallel to regulatory planning, we carry out a structured market analysis: We identify your target markets, evaluate segment size and growth potential, analyze the competition and determine clinical needs. It is crucial to define the relevant target groups along the care pathway, from clinics, practices and medical care centers to prescribing physicians, payers and purchasers. <\/p>\n

We develop a specific value proposition for each stakeholder group: What specific benefits does your product offer? How does it improve treatment outcomes, workflows or cost efficiency? These value propositions form the basis for your entire commercial strategy. We also take the patient journey into account to understand where and how patients come into contact with your product and which decision-makers are relevant along the way. A sound target customer analysis prevents you from investing valuable resources in market segments that do not need your product or are not willing to pay for it. <\/p>\n<\/div><\/div><\/div>

Go-to-market plan and
\nRoute-to-market<\/p><\/h3><\/div>

Based on the market and target customer analysis, we work out your positioning in the competitive environment: are you a pioneer in a new segment, do you occupy a specific niche or do you offer an improved alternative to existing solutions? From this, we derive your desired market role and develop pricing and revenue models that are realistic in the context of reimbursement options, budget impact and procurement logic. <\/p>\n

A key aspect is defining the route to market: we analyze whether direct sales, partnerships, distributors or digital platforms are the right sales channels for your product. We develop the appropriate sales and launch activities – from training your sales team and developing product materials to planning initial conference appearances and involving key opinion leaders. Especially in the medical device market, credible communication about clinical data and real-world evidence is crucial to convince doctors and payers.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>

Thinking strategically about reimbursement and market access<\/h2><\/div><\/div><\/div>

In Germany and many EU countries, eligibility for reimbursement determines commercial success. We integrate market access considerations into your launch strategy right from the start: In the outpatient sector, the approval requirement applies, i.e. medical devices require a positive decision by the Federal Joint Committee or must be listed as an aid. In the inpatient sector, other mechanisms such as NUB procedures or integration into DRG flat rates apply. <\/p>\n<\/div><\/div><\/div>

We support you in the strategic planning of this market access measure<\/h3><\/div>

Which reimbursement paths are relevant for your product? When do which applications need to be submitted? What clinical or health economic data is required? <\/p>\n

We clarify these questions at an early stage so that reimbursement hurdles do not become a showstopper after approval. In the case of digital health applications, we also support the DiGA approval process with its specific requirements for proof of benefit. <\/p>\n<\/div><\/div><\/div>

<\/span><\/div><\/div><\/div>

Launch roadmap and
\ncontinuous monitoring<\/p><\/h2><\/div><\/div><\/div>

The result of our work is an integrated launch roadmap: it combines all activities from development, clinical trials, approval milestones and market access procedures to the sales launch, initial customer references, conference appearances and KOL activities. This roadmap makes dependencies transparent, avoids bottlenecks and ensures coordinated implementation across all teams involved. <\/p>\n

We define measurable KPIs for your launch success: meeting approval deadlines, time to reimbursement, adoption in target clinics or practices, initial sales targets and customer feedback metrics. At the same time, we set up feedback and monitoring mechanisms so that you can react quickly to market changes, regulatory adjustments or unexpected product weaknesses after the launch. A successful launch does not end on the day of the market launch – the post-launch phase requires continuous adjustment and optimization. <\/p>\n<\/div><\/div><\/div>

Your advantage with BAYOOCARE<\/h2><\/div><\/div><\/div>

With our launch strategy, you systematically reduce regulatory and commercial risks because classification, approval strategy and market entry planning are integrated from the outset. You gain a clear, realistic roadmap with defined responsibilities, milestones and KPIs. This enables you to make the path to market launch transparent to investors, stakeholders and internal teams and to manage resources in a targeted manner. <\/p>\n

We take care of both the strategic conception and – if required – the operational support for your market launch. You benefit from our expertise within the YOOme group of companies: from technical documentation and UX design to software development, we can draw on experts if required. Our goal is to ensure that your innovative medical device is not only approved, but also successfully established on the market. <\/p>\n<\/div><\/div><\/div>

\"BAYOOCARE<\/span><\/div><\/div><\/div><\/div><\/div>

Frequently asked questions about the
\nlaunch strategy<\/p><\/h2><\/div><\/div><\/div>

A successful market launch raises many questions. We have answered the most common ones for you – from the right MDR risk classification to market access strategies and go-to-market planning. Your question is not listed? Please feel free to contact us. <\/p>\n<\/div><\/div><\/div>

<\/span><\/div><\/div><\/div>

<\/i><\/i><\/span>When should I start planning a launch strategy?<\/span><\/a><\/h4><\/div>
Ideally, the development of a launch strategy should begin two to three years before the planned market entry. The more innovative your medical device is, the longer the approval process, clinical studies and market access measures will take. Early planning makes it possible to dovetail regulatory requirements with product development and prevents expensive rework. Involving key opinion leaders and preparing the market also takes time. <\/div><\/div><\/div>

<\/i><\/i><\/span>How long does an MDR approval for medical devices take?<\/span><\/a><\/h4><\/div>
\n

The duration depends on the risk class. Class I products usually allow self-certification within several months. Products in Class IIa and higher require a Notified Body with an average processing time of twelve to eighteen months. You should allow eighteen to twenty-four months for higher risk classes, including setting up the quality management system. <\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>What does it cost to develop a launch strategy?<\/span><\/a><\/h4><\/div>
\n

The costs vary depending on the complexity of your product, risk class and target market. A well-founded launch strategy includes market analyses, regulatory advice, target group analyses and go-to-market planning. However, this investment pays off: Without a well-thought-out strategy, the costs for product improvements, catch-up clinical studies or delayed market access are significantly higher. We will be happy to provide you with an individual offer based on your specific requirements and discuss various scopes of services. <\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>Do I need a launch strategy for every medical device?<\/span><\/a><\/h4><\/div>
\n

Not every product requires a comprehensive launch strategy. Marketing and sales campaigns are often sufficient for accessories, consumables or product variants. However, a launch strategy is crucial for truly innovative products, new markets, higher risk classes or when new treatment methods are introduced. The more disruptive your innovation and the more complex the regulatory and commercial context, the more essential a structured launch strategy is for your success. <\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>How do market access and reimbursement differ in Germany?<\/span><\/a><\/h4><\/div>
\n

The CE marking allows your product to be placed on the market in the EU. However, reimbursement by statutory health insurance funds is separate from this. In the outpatient sector, the authorization requirement applies – new methods with medical devices require a G-BA assessment or listing as an aid. In the inpatient sector, innovative products can also be reimbursed via NUB procedures. CE marking is a prerequisite for reimbursement, but does not guarantee it. <\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>What is the difference between a launch strategy and a go-to-market plan?<\/span><\/a><\/h4><\/div>
\n

The launch strategy is the overarching framework that integrates regulatory, clinical and commercial considerations. It defines target markets, positioning, timelines and strategic decisions such as pricing or sales models. The go-to-market plan is the operational part: it describes specific measures, responsibilities, budgets and timelines for implementation. Both belong together, a good strategy without an operational plan remains theory, a plan without a strategic foundation rarely leads to success. <\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>

\"BAYOOCARE<\/span><\/div><\/div><\/div>

Alfred Koch<\/strong><\/p>\n

CEO | PRRC<\/p>\n<\/div><\/div><\/div><\/div>

How to contact us<\/h4><\/div>

Are you planning a project or do you have very specific regulatory questions about placing your medical device on the market? No matter what phase of your project you are in, we will be happy to support you. The quickest way to reach us – feel free to write to us.<\/p>\n<\/div><\/div><\/div>

<\/div>

Contact form<\/h4><\/div>